12 Panel Drug Test Dip Cards

Twelve-substance urine drug test dip cards from the manufacturer the panel is named after. As the producer of the Serenity brand drug testing product line, 12 Panel Now supplies the 12 panel dip card in two CLIA Waived configurations: the PCP format (AMP/BAR/BUP/BZO/COC/MDMA/MET/MTD/OPI/OXY/PCP/THC) for correctional, forensic, and workplace settings, and the TCA format (AMP/BAR/BUP/BZO/COC/MDMA/MET/MTD/OPI/OXY/TCA/THC) for clinical and healthcare programs monitoring tricyclic antidepressant use. Both are CLIA Waived, FDA-cleared, and deliver 99% accuracy with results in 5 minutes. From $1.19 per test. Same-day wholesale shipping before 3:00 PM EST.

Shop 12 Panel Drug Test Dip Cards (PCP and TCA configurations) — CLIA Waived — from $1.19

What Does a 12 Panel Drug Test Dip Card Detect?

A 12 panel drug test dip card screens for twelve substances in a single urine dip, delivered in one of two CLIA Waived configurations: the PCP format covering AMP, BAR, BUP, BZO, COC, MDMA, MET, MTD, OPI, OXY, PCP, and THC, or the TCA format that replaces PCP with Tricyclic Antidepressants. At 12 Panel Now, both configurations of the 12 Panel Drug Test Dip Card are CLIA Waived and FDA-cleared, using twelve dedicated lateral flow immunoassay strips in a single card housing with photocopy-compatible result windows and a 5-minute read time. The 12-panel is the most searched panel count in the drug testing category and the product that defines this company. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now produces all 12-panel dip cards to the quality standards applied across its full product range, from the most sensitive analyte — BUP at 10 ng/mL — to the broadest-window detection analyte, BAR, which can remain positive for up to three weeks in chronic phenobarbital users. The SAMHSA Drug-Free Workplace Program classifies the 12-panel as an employer-level expanded screening format that builds on the federal 5-panel baseline by adding seven additional analytes covering prescription opioids, sedatives, sedative-hypnotics, and dissociatives.

Why Does the 12 Panel Dip Card Come in Two Configurations?

The eleven substances shared by both configurations — AMP, BAR, BUP, BZO, COC, MDMA, MET, MTD, OPI, OXY, and THC — represent the analytically stable core of the 12-panel format. The twelfth position reflects a clinical choice about which risk the program prioritizes: PCP for programs in environments where phencyclidine is a documented substance of abuse or adulterant in illicit drug supplies, or TCA for clinical and healthcare settings where tricyclic antidepressant monitoring is medically meaningful. This is not an arbitrary split. PCP at 25 ng/mL is the most sensitive analyte on the 12-panel dip card and provides detection for up to two weeks in heavy users. TCA at 1000 ng/mL detects tricyclic antidepressants such as amitriptyline, nortriptyline, imipramine, and doxepin at concentrations associated with recent prescription use. Browse both variants at the 12 Panel Drug Test Dip Card product page to select the configuration that matches your program’s population risk profile.

What Is BAR on a Drug Test and Why Is It on the 12-Panel?

BAR stands for Barbiturates, a class of sedative-hypnotic central nervous system depressants that includes phenobarbital (Luminal), secobarbital (Seconal), butalbital (Fiorinal), and amobarbital, with the strip detecting metabolites at 300 ng/mL and a detection window ranging from 2 days for short-acting compounds to 3 weeks for chronic phenobarbital use. Barbiturate use peaked in clinical medicine in the mid-20th century and was largely replaced by benzodiazepines in prescribing practice from the 1970s onward. However, several factors make BAR detection clinically relevant on the 12-panel in 2026. Phenobarbital remains a legitimately prescribed antiepileptic drug and is the drug of choice in several neonatal seizure and refractory epilepsy protocols. Butalbital is still present in commonly prescribed migraine medications including Fiorinal and Fioricet, making inadvertent BAR positives from legitimate prescriptions a meaningful clinical possibility in any monitored population. Illicitly, barbiturates circulate in some street drug markets — particularly in regions where short-acting barbiturates such as secobarbital are misused as sedatives or as adulterants in other drug supplies. The NIH clinical pharmacology overview of barbiturates confirms that barbiturate compounds potentiate GABA receptor activity and produce dose-dependent CNS depression ranging from mild sedation to respiratory arrest at high doses, explaining why BAR detection is both clinically and safety-relevant in programs monitoring sedative misuse.

Are Barbiturates Still Commonly Misused in 2026?

Barbiturate misuse is less prevalent than benzodiazepine misuse in most US demographics, but it remains clinically significant in several specific contexts. Butalbital-containing prescription headache medications are the most commonly encountered source of BAR-positive results in professional drug testing, since the butalbital component produces metabolite concentrations detectable at 300 ng/mL within the therapeutic dose range. Programs that encounter a BAR-positive result should first verify whether the donor holds a valid prescription for a butalbital-containing medication before escalating to a compliance action. Phenobarbital use in epilepsy management produces consistent BAR-positive results at therapeutic dosing, again requiring prescription verification as the first step in result interpretation. For correctional and forensic settings, illicit barbiturate misuse remains a monitoring priority because barbiturate-opioid co-use produces the same type of compounded respiratory depression risk as the benzodiazepine-opioid combination documented by the CDC in its overdose mortality surveillance. Any presumptive positive on the BAR strip requires GC-MS or LC-MS/MS laboratory confirmation before consequential action, particularly because the 300 ng/mL cutoff will flag therapeutic butalbital use.

PCP Configuration vs TCA Configuration: Which 12 Panel Should Your Program Choose?

Choose the PCP configuration if your program operates in a correctional, forensic, law enforcement, or high-risk workplace setting where phencyclidine use or PCP-adulterated drug supplies are a documented concern in your population. Choose the TCA configuration if your program is a clinical or healthcare setting that prescribes or monitors tricyclic antidepressant medications or manages patients with dual-diagnosis profiles where TCA overdose risk is clinically meaningful. The PCP variant (SKU: SM-DOA-6125) at $1.19 is the lower-cost standard configuration and the appropriate choice for the majority of non-clinical programs. The 25 ng/mL PCP cutoff is extremely sensitive and will detect phencyclidine use within the prior 7 to 14 days in regular users. Correctional facilities and probation programs managing participants in areas where PCP use is regionally documented should use the PCP configuration. The TCA configuration is appropriate for pain management clinics, psychiatric practice drug testing, and healthcare settings where patients may be prescribed amitriptyline for neuropathic pain, imipramine for depression, or nortriptyline for mood disorders. In those settings, a TCA-positive result carries direct clinical significance because tricyclic antidepressants have a narrow therapeutic window and significant drug interaction potential with opioids and sedatives. Both configurations are available at the 12 Panel Drug Test Dip Card product page.

What Is TCA on a Drug Test?

TCA stands for Tricyclic Antidepressants, a class of medications that includes amitriptyline (Elavil), nortriptyline (Pamelor), imipramine (Tofranil), doxepin (Sinequan), and clomipramine (Anafranil). The TCA strip at 1000 ng/mL on the 12-panel dip card detects concentrations of TCA metabolites consistent with recent prescription use at therapeutic doses. Tricyclic antidepressants are prescribed for depression, neuropathic pain, fibromyalgia, migraines, and several other conditions, meaning TCA-positive results in clinical drug testing frequently reflect legitimate therapeutic use. The clinical reason for including a TCA strip in a 12-panel monitoring program is twofold. First, TCA overdose is a life-threatening medical emergency that produces cardiotoxicity, seizures, and coma at doses not much higher than therapeutic levels — knowing a patient is taking TCAs informs the clinical risk calculus for any program prescribing sedatives, opioids, or other CNS-active medications alongside them. Second, TCA misuse and self-harm via intentional overdose is documented in populations with depression histories, making TCA screening in mental health and addiction medicine contexts a safety monitoring tool as much as a compliance tool. The NIH clinical toxicology overview of TCA poisoning identifies tricyclic antidepressant overdose as one of the leading causes of prescription drug-related death and emergency department visits, which is the safety context in which TCA monitoring matters most. All TCA presumptive positives must be confirmed by laboratory GC-MS or LC-MS/MS before any clinical or compliance action is taken.

Does the 12 Panel Drug Test Detect Fentanyl?

No. The standard 12 panel drug test dip card does not detect fentanyl. Fentanyl requires its own dedicated FEN strip at 20 ng/mL and is not captured by the OPI opiate analyte on any panel. This is the most frequently searched question about the 12-panel in 2025 and 2026, driven by the HHS Federal Register mandate of January 2025 adding fentanyl to the authorized federal testing panel effective July 7, 2025. Programs running a 12-panel and relying on the OPI strip to detect fentanyl are missing every fentanyl-positive specimen in their population. According to the Quest Diagnostics 2025 Drug Testing Index, fentanyl was detected in 1.13% of random workforce drug tests in 2024, with 60% of those specimens also testing positive for another substance — meaning fentanyl-positive individuals are almost always also positive for a substance the 12-panel does detect, but that OPI co-positive does not eliminate the need for a dedicated FEN analyte. 12 Panel Now offers the single panel fentanyl dip card at 20 ng/mL as a supplemental add-on for programs using the 12-panel that need fentanyl coverage, as well as fully integrated 13-panel and higher dip card configurations that include FEN as a built-in strip.

Which 12 Panel Now Product Includes Fentanyl at the 12-Panel Tier?

12 Panel Now offers CLIA Waived dip card configurations that include fentanyl alongside the standard 12-panel substance baseline. These include the CLIA Waived format with FEN/20 and norFentanyl (NFYL) starting from $1.27, providing both the parent fentanyl compound and its primary active metabolite norfentanyl in a single dip card. The norfentanyl strip at 5 ng/mL is particularly valuable because norfentanyl persists in urine longer than fentanyl itself, extending the detection window beyond the 24 to 72 hour window typical for fentanyl alone. These fentanyl-configured variants are available at the 12 Panel Drug Test Dip Card product page. For programs in CLIA Waived clinical settings that need fentanyl detection as part of a comprehensive patient monitoring protocol, the fentanyl-configured 12-panel variant provides compliance with the post-July 2025 federal substance authorization standard in a single CLIA Waived dip.

Who Uses the 12 Panel Drug Test Dip Card?

The 12 panel drug test dip card is used by the broadest range of institutional buyers in the drug testing market: pain management clinics, MAT programs, probation offices, correctional facilities, sober living homes, rehab centers, occupational medicine programs, healthcare staffing agencies, and employers in safety-sensitive industries who need a comprehensive substance screen with both opioid compliance coverage and sedative-hypnotic monitoring in a single CLIA Waived dip. Pain management clinics use the 12-panel because it simultaneously covers OXY for oxycodone compliance, OPI for illicit opiate detection, BUP for buprenorphine monitoring, BZO and BAR for sedative co-use, and MDMA alongside the stimulant and cannabis baseline. Buprenorphine treatment programs use the 12-panel because it covers more substances than the 10-panel while maintaining CLIA Waived status and staying below the cost threshold of cup formats at high testing frequency. Correctional facilities use the PCP configuration because the 25 ng/mL threshold provides the most sensitive detection available in a rapid dip format for a substance that remains problematic in incarcerated populations and in drug supplies entering controlled environments. Sober living homes use the 12-panel because it provides the broadest standard substance coverage in a CLIA Waived single dip at under $1.25 per test, covering every substance class that most commonly causes relapse in the residential treatment population.

Is the 12 Panel Drug Test the Right Format for Workplace Drug Testing?

For non-DOT employers, the 12 panel is one of the most commonly adopted expanded baseline formats in 2026. DOT-regulated employers are required to use the federal 5-panel minimum — but non-DOT employers have discretion to configure any panel that serves their documented risk profile. The 12-panel’s coverage of BAR, BUP, MDMA, MTD, and OXY beyond the standard 5-panel baseline makes it appropriate for employers in healthcare, logistics, construction, manufacturing, and other safety-sensitive industries where the prescription opioid and sedative use patterns of their workforce represent meaningful safety and liability risks. Employer workplace drug testing programs that have moved from a 5-panel to a 12-panel typically do so after a post-accident investigation reveals that the substance involved was not covered by the existing panel. The OSHA Drug-Free Workplace guidelines document that panel configuration decisions should be driven by the specific substance risk profile of the workplace and workforce, and that the 5-panel federal minimum does not bind non-regulated employers who want broader coverage. For DOT-regulated employers, the 5-panel remains the mandatory format — the 12-panel dip card is appropriate for supplemental non-safety-sensitive employee screening or for voluntary expanded screening outside the regulated testing program.

How Does the 12 Panel Dip Card Differ From the 10 Panel?

The 12 panel dip card adds Barbiturates (BAR/300) and either PCP (25 ng/mL) or TCA (1000 ng/mL) to the 10-panel baseline — these two additional analytes are the only analytical difference between the formats, and the right choice between them depends on which additional substance category is relevant to the program’s monitored population. The 10 panel dip card covers AMP, BUP, BZO, COC, MDMA, MET, MTD, OPI, OXY, and THC. The 12-panel retains all ten of those analytes and adds two more. For programs that have already moved to the 10-panel and whose population has no documented barbiturate use and no history of PCP or TCA relevance, the 10-panel remains the more cost-efficient choice at $0.99 versus $1.19. For programs where any donor is prescribed phenobarbital for epilepsy, butalbital for migraines, or a tricyclic antidepressant for any indication, and where that medication use needs to be documented and monitored alongside drug screening, the 12-panel is the appropriate upgrade. For programs in regions or institutions where PCP use is locally documented, the 12-panel PCP configuration is the correct choice regardless of cost differential, because a 10-panel program is completely blind to phencyclidine.

When Should a Program Move From 12 Panel to a Higher-Count Dip Card?

The 12-panel is not the right format for programs whose population has documented fentanyl exposure risk, which requires a dedicated FEN strip not present in the standard 12-panel configuration. It is also not appropriate as the sole monitoring tool for programs where gabapentin misuse is a documented concern — GAB requires its own dedicated strip first available in 15-panel and higher configurations. Programs monitoring populations with K2 or synthetic cannabinoid use need a K2 analyte not present in the 12-panel. Kratom detection requires a dedicated KRA strip available in 16-panel and higher dip cards. Programs needing two or more of these additional analytes alongside the 12-panel baseline should evaluate the 13 through 19 panel dip card formats that systematically add FEN, NFYL, GAB, K2, KRA, and other emerging substance analytes while maintaining the 12-panel baseline as their core. The dip card format guide provides a detailed comparison of available configurations and analyte combinations to help programs select the right panel count for their specific monitoring requirements.

What Does the 12 Panel Drug Test NOT Detect?

The standard 12 panel drug test dip card does not detect fentanyl, norfentanyl, gabapentin, kratom, K2 or synthetic cannabinoids, tramadol, xylazine, ketamine, MDPV, psilocybin, LSD, delta-8 THC, or any substance beyond its twelve dedicated strips. The OPI strip at 300 ng/mL detects morphine, codeine, and heroin metabolites but will not detect fentanyl, hydrocodone at typical doses, or buprenorphine. The THC strip at 50 ng/mL detects delta-9 THC metabolites consistent with cannabis use but does not detect synthetic cannabinoids, delta-8 THC from legal hemp-derived products, or K2/Spice. Programs operating in states with widespread legal cannabis access should be aware that the 50 ng/mL THC cutoff reflects SAMHSA-standard threshold calibration for delta-9 THC metabolites — hemp-derived CBD products with trace THC contamination will typically not produce a positive result at this cutoff, but high-dose CBD use from non-compliant products occasionally produces THC metabolite concentrations that exceed 50 ng/mL. The complete absence of fentanyl detection is the most consequential gap in the standard 12-panel for programs in 2026. The single panel fentanyl dip card at 20 ng/mL can be used alongside the standard 12-panel as a targeted supplement, or programs can order the fentanyl-configured CLIA Waived 12-panel variant that includes FEN and NFYL as integrated strips.

How Accurate Is the 12 Panel Drug Test Dip Card?

The 12 panel drug test dip card delivers 99% accuracy across all twelve analytes when administered correctly per manufacturer instructions, with CLIA Waived FDA clearance confirming its validation for use by minimally trained operators in non-laboratory settings. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now produces all 12-panel dip cards to the consistent quality control standards that apply across the full range. The most sensitive analyte on the card is BUP at 10 ng/mL, which is also the most susceptible to procedural error. Insufficient dip time below 10 seconds, specimen contact with the plastic housing above the dip line, or reading results outside the 5 to 10 minute window can affect BUP strip reliability more significantly than higher-cutoff strips. The PCP strip at 25 ng/mL is similarly sensitive and benefits from strict adherence to the read window. The BAR strip at 300 ng/mL is among the more robust analytes and is less likely to produce procedural artifacts from minor dip time variation. For all twelve analytes, any presumptive positive result — defined as a single colored band appearing only in the control (C) region with no band in the test (T) region — must be confirmed by GC-MS or LC-MS/MS certified laboratory testing before any employment, clinical, or legal consequence is applied. The SAMHSA Drug-Free Workplace FAQ explicitly requires laboratory confirmation of all positive rapid immunoassay screening results before final determination.

How Do You Read the 12 Panel Dip Card Results?

Remove the dip card from its sealed foil pouch immediately before use. Remove the cap from the absorbent strip end of the card. Immerse the strip end into the fresh urine specimen for 10 to 15 seconds, keeping the urine level below the dip line marked on the card housing. Do not allow the specimen to contact the plastic housing above the dip line. Replace the cap and lay the card flat on a clean, non-absorbent surface. Read results at exactly 5 minutes. Do not read after 10 minutes. For each of the twelve strips, two visible colored bands in both the control (C) and test (T) regions indicate a negative result for that substance. A single band appearing only in the control region, with no band in the test region, is a presumptive positive for that analyte. No band in the control region on any strip indicates an invalid test — discard the card, collect a new specimen, and retest with a fresh card. The result windows on the 12-panel dip card are photocopy-compatible: the card can be photocopied for record documentation without opening or altering the specimen-contacted card. For a detailed visual guide to reading rapid drug test results across different configurations, visit the Dip Cards Explained guide at 12 Panel Now.

12 Panel Drug Test Dip Card vs 12 Panel Drug Test Cup

Both formats detect the same twelve substances at equivalent immunoassay accuracy. The dip card at $1.19 is the lower-cost format for high-volume monitoring programs where cost efficiency and field portability matter. The cup format provides integrated specimen collection, built-in temperature validity confirmation, and tamper-evident sealed design for settings with chain-of-custody requirements. The 12 panel drug test cup integrates collection and testing in a sealed device where the donor urinates directly into the cup. Results appear through integrated test windows without the need to open the container, and the built-in temperature strip validates specimen temperature within the 90 to 100 degrees Fahrenheit range consistent with a fresh voided specimen. The dip card requires a separate clean collection container. For rehabilitation centers and methadone treatment programs testing 50 to 300 patients per day where observed collection with direct clinical oversight is standard, the dip card at $1.19 versus the cup’s higher price point represents significant monthly savings on an identical 12-substance screen. For employer programs with chain-of-custody documentation requirements or post-accident testing protocols where specimen integrity must be defensible, the cup format is the appropriate choice regardless of cost differential.

Is the 12 Panel Dip Card CLIA Waived?

Yes. The standard 12 panel drug test dip card at 12 Panel Now is CLIA Waived and FDA 510(k) cleared, including the PCP configuration, the TCA configuration, and the fentanyl-configured CLIA Waived variants. CLIA Waiver status confirms that the device has been validated by the FDA as posing minimal risk of harm from incorrect use and cleared for use in any non-laboratory clinical setting by operators without advanced laboratory training. This includes physician offices, urgent care facilities, occupational medicine clinics, corrections healthcare units, employee health services, and any other point-of-care setting that needs to administer drug testing under clinical oversight without operating a certified laboratory. The CLIA Waived designation on the 12-panel dip card matters operationally because it means a nurse, medical assistant, or trained healthcare aide can administer the test in a clinical setting without requiring a laboratory technician or phlebotomist, reducing the operational cost of high-frequency monitoring programs. For programs uncertain whether a specific rapid test carries CLIA Waived status, the CLIA Waived verification guide at 12 Panel Now explains how to confirm waived status through the FDA 510(k) database and the CMS waived test directory. The CDC’s waived test classification guidance provides the regulatory framework for understanding how the waived category applies to point-of-care drug testing devices.

What Settings Require a CLIA Waived 12 Panel Drug Test?

Any clinical healthcare setting administering a rapid drug test at the point of care must either hold a CLIA certificate for the appropriate complexity level or use a CLIA Waived test. Physician offices, community health centers, federally qualified health centers, employee health clinics, occupational medicine practices, and school-based health services all fall under CLIA jurisdiction when administering laboratory tests including rapid drug screening. For these settings, using a non-waived forensic use only (FUO) drug test in a patient care context would represent a CLIA compliance issue. The 12-panel dip card’s CLIA Waived status removes this barrier entirely, making it the correct choice for any clinical program that administers drug testing to patients rather than to job applicants, parolees, or participants in non-clinical monitoring programs. Programs that need to screen patients for substance use as part of a clinical assessment, a medication reconciliation process, or an opioid treatment protocol initiation can use the CLIA Waived 12-panel dip card as a point-of-care tool in the clinical encounter without any additional regulatory authorization beyond the standard CLIA Waived certificate of registration that most physician practices already hold.

What Programs Commonly Require a 12 Panel Drug Test?

No federal regulation mandates the 12-panel specifically — it is an institutional decision made by programs whose population risk profile requires broader substance coverage than the 5-panel DOT baseline, the 7-panel OXY-addition format, or the 10-panel MDMA-baseline format can provide. Drug court programs commonly require a 12-panel because their participants have complex polydrug histories requiring BAR, MDMA, PCP, and TCA monitoring alongside the opioid-sedative-stimulant baseline. Probation departments managing participants with prior convictions involving multiple substance classes adopt the 12-panel as their standard format because it closes coverage gaps that lower panel counts leave open. Correctional facilities use the 12-panel PCP configuration because PCP remains a documented substance of abuse in incarcerated populations in several US regions and the 25 ng/mL detection threshold provides the sensitivity needed for correctional-grade screening. Healthcare staffing agencies conducting pre-employment drug testing for nurses, pharmacists, and allied health workers frequently use the 12-panel because the healthcare worker population has elevated access to the prescription medications detected by the BAR, TCA, BUP, and OXY strips, and broader coverage is warranted. Many MAT programs have upgraded to the 12-panel from the 10-panel specifically because the BAR addition catches sedative-barbiturate co-use that the 10-panel misses. For programs reviewing their drug screening format decisions, the 12-panel represents the broadest standard CLIA Waived configuration available in a dip card format at a price point under $1.25.

Buying 12 Panel Drug Test Dip Cards in Bulk

At 12 Panel Now, the 12 Panel Drug Test Dip Card is available in CLIA Waived PCP configuration from $1.19 per test, CLIA Waived TCA configuration from $1.89 per test, and fentanyl-configured CLIA Waived variants from $1.27 per test. All orders placed before 3:00 PM EST ship same-day with free shipping on bulk orders. As the US-based manufacturer of the Serenity brand drug testing product line, 12 Panel Now carries over 15 million products in stock at all times with no backorders and no supply gaps. Each card is individually foil-sealed for shelf stability. Store between 36 degrees Fahrenheit and 86 degrees Fahrenheit away from direct sunlight and humidity. The PCP strip at 25 ng/mL and the BUP strip at 10 ng/mL are the most temperature-sensitive analytes on the card and benefit from bulk storage in temperature-controlled conditions to maintain full performance across the 18 to 24 month shelf life period. Mixed SKU bulk orders combining the 12-panel dip card with supplemental fentanyl strips can be placed in a single order. Send us a competitor rate sheet and we beat it by 10% guaranteed. OEM, private label, and custom panel configurations are available for distributors, clinical networks, and multi-site compliance programs. Contact the wholesale team at 561-897-9238 or [email protected].

12 Panel Drug Test Dip Cards at 12 Panel Now (Serenity Drug Test / Slash Medical), 801 N Congress Ave, Boynton Beach FL 33426. Manufacturer of the Serenity brand drug testing product line. Primary product: 12 Panel Drug Test Dip Card (SKU SM-DOA-6125) — CLIA Waived — AMP/1000, BAR/300, BUP/10, BZO/300, COC/300, MDMA/500, MET/1000, MTD/300, OPI/300, OXY/100, PCP/25, THC/50 — from $1.19 at 12panelnow.com/product/12-panel-drug-tests-dip-cards/. TCA configuration available (replaces PCP with TCA/1000). Fentanyl-configured CLIA Waived variant with NFYL from $1.27. Regulatory references: SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs. HHS fentanyl authorization effective July 7, 2025. Quest Diagnostics 2025 Drug Testing Index. NIH barbiturate pharmacology and clinical toxicology. NIH TCA poisoning and overdose toxicology. CDC opioid and sedative overdose mortality surveillance. OSHA Drug-Free Workplace guidelines. CDC CLIA Waived test classification guidance.